-
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland, Columbus
-
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Canton, Cincinnati, Columbus
-
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus
-
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
NCT06822738 ·
Phase: Phase 3 ·
Ages: 45 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland
-
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240 ·
Phase: Not specified ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
NCT06632379 ·
Phase: Phase 4 ·
Ages: 20 Years to 50 Years ·
Sex: Female
· Ohio: Columbus
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
NCT06055036 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· Ohio: Columbus
-
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus
-
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
NCT06402968 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Ohio: Akron, Cleveland, Toledo
-
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland, Columbus
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus, Westlake
-
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT06468202 ·
Phase: Phase 4 ·
Ages: 14 Years to 35 Years ·
Sex: Female
· Ohio: Columbus
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Evaluating Whether Treating Elevated Blood Pressure in the Inpatient Setting Impacts Patient Outcomes
NCT07208669 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland, Mayfield Heights
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia
NCT02986087 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 50 Years ·
Sex: Female
· Ohio: Cincinnati
-
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
NCT06057051 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 35 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
NCT07477197 ·
Phase: Not specified ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Home BP Monitoring
NCT05552547 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 13 Years to 18 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 45 Years and older ·
Sex: All (male and female)
· Ohio: Brecksville, Cincinnati, Mason
-
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
NCT07232017 ·
Phase: Not specified ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398 ·
Phase: Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study
NCT07363343 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Ohio: Cleveland
-
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT05293756 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 50 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Office, Home, and Ambulatory Blood Pressure
NCT05297708 ·
Phase: Not specified ·
Ages: 6 Years to 19 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
NCT07058155 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
NCT02249923 ·
Phase: Not specified ·
Ages: 1 Day to 21 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 ·
Phase: Not specified ·
Ages: 0 Years to 20 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
NCT04669548 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Pulmonary Hypertension Association Registry
NCT04071327 ·
Phase: Not specified ·
Ages: 0 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension
NCT07209254 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Ohio: Columbus
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 45 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Safety and Efficacy of FETO in CDH Phase III
NCT07187206 ·
Phase: Phase 3 ·
Ages: 18 Years to 50 Years ·
Sex: Female
· Ohio: Cincinnati
-
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Beavercreek
-
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712 ·
Phase: Phase 2 ·
Ages: 1 Year to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
NCT06343298 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Marion
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Beavercreek, Cincinnati, Columbus, Dayton